Sulidor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulidor

Property Description
Active ingredient Nimesulide
Form Tablet, Granules for Oral Suspension, Topical Gel
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Analgesic, Anti-inflammatory, Antipyretic
Origin Synthetic Compound (Sulfonamide derivative)

Sulidor: Definition, Composition, and Chemical Origin

Sulidor is a medicinal preparation defined by its active ingredient, Nimesulide, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Nimesulide is a synthetic compound that chemically belongs to the sulfonamide class, specifically recognized as a methanesulfonanilide derivative. This chemical structure establishes Nimesulide as a non-acidic NSAID, a factor that distinguishes it from many older acidic analogues. Pharmacological studies have clinically recognized Nimesulide for its relatively fast onset of action, providing effective pain relief and exhibiting fever-reducing properties. This medicine is indicated to help ease acute discomfort and lower body temperature when it is elevated.

Pharmacological Type: A Selective Anti-inflammatory Agent

Sulidor functions pharmacologically as a Cyclooxygenase-2 (COX-2) selective inhibitor, which is its distinguishing mechanism within the NSAID category. This selectivity means the drug is designed to preferentially target the COX-2 enzyme, the primary source of key inflammatory chemical mediators in the body. Unlike non-selective agents, this focus is intended to reduce the inflammatory response. The Anatomical Therapeutic Chemical (ATC) classification system places Nimesulide within the category of anti-inflammatory and anti-rheumatic products that are non-steroidal. This classification confirms its defined role in managing inflammation, a common use scenario being the temporary relief of discomfort associated with painful symptoms.

General Purpose and Available Preparations

To fulfill its general purpose—to provide analgesic (pain relief), anti-inflammatory, and antipyretic (fever reducer) effects—the active ingredient is formulated into several pharmaceutical preparations. These include forms for oral administration, such as standard tablets and specialized granules for oral solution or powder for oral suspension, as well as a topical preparation (gel) designed for localized action. This range of forms allows the medicine to be administered appropriately depending on the required route of action, offering flexibility not always present in single-form NSAIDs.

What side effects are possible with Sulidor?

Possible Side Effects and Safety Information

The safety profile of Sulidor (Nimesulide) is formally structured around classifications defined by regulatory health authorities. The officially documented adverse reactions are categorized by frequency and the body system affected, with the most critical concerns focused on the Hepatobiliary (liver) and Gastrointestinal (stomach and intestines) systems.


Frequency Classification of Adverse Reactions

The occurrence of adverse reactions is classified using standard regulatory terminology:

  • Common: Diarrhoea, Nausea, Vomiting, and increases in liver enzymes (transaminases).
  • Uncommon: Vertigo, Vomiting, Gastric haemorrhage, Gastrointestinal ulceration, Rash.
  • Rare/Very Rare: These categories include serious reactions such as Anaphylaxis, Fulminant hepatitis, Severe Skin Reactions (e.g., Stevens-Johnson syndrome), and Gastrointestinal bleeding/perforation.

Safety Considerations and Restrictions

Official regulatory documents define specific safety constraints and population-related considerations. The most serious concern is Hepatotoxicity, which can occur rapidly, leading regulatory bodies to impose a strict maximum treatment duration of 15 days for the oral formulation to mitigate this risk.

Use of Sulidor is formally contraindicated (prohibited) in specific patient populations or conditions due to the risk of severe adverse outcomes. These include individuals with severe hepatic impairment, severe renal impairment, active or history of peptic ulcer/haemorrhage, and severe heart failure. Furthermore, older adults are noted in the prescribing information as having an increased frequency of serious adverse reactions, particularly gastrointestinal issues.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Acute overdose of Sulidor (Nimesulide) is documented in regulatory sources to present with general symptoms such as lethargy, drowsiness, nausea, vomiting, and epigastric pain. Less common signs that have been reported include Hypertension, Tachycardia, Headache, and Visual disturbance.

Overdose carries a risk of severe or life-threatening systemic outcomes. These can include Gastrointestinal bleeding and potentially fatal Gastrointestinal ulceration/perforation. Critically, the drug is associated with serious hepatic reactions, including acute liver failure and, in very rare cases, fatal outcomes. Other severe possibilities include acute renal failure, respiratory depression, and coma.

Emergency Actions and Management

Immediate medical attention is required in the event of an overdose.

  • Mandated Action: Treatment must be discontinued immediately if a patient experiences clinical signs compatible with hepatic injury, such as anorexia, fatigue, or dark urine. These individuals must not be rechallenged with the medicine.
  • Management: Management of overdose is limited to symptomatic and supportive care.
  • Antidote Status: No specific antidote is documented as being known for the overdose of this drug, according to official regulatory information.

Population Considerations

Regulatory documents note that elderly patients are particularly susceptible to severe NSAID adverse effects, including risks of hemorrhage and organ impairment. The systemic formulation is contraindicated in children under 12 years and in patients with severe renal impairment, reflecting increased risk in these populations.

Therapeutic Uses of Sulidor

What Sulidor Treats: Main Uses and Benefits

Sulidor (Nimesulide) provides symptomatic relief across several distinct therapeutic domains, primarily targeting pain, inflammation, and fever. It is applied in contexts where temporary assistance in symptom stabilization is appropriate to ease the overall burden of acute discomfort.

The active substance is considered relevant for the short-term symptomatic management of acute pain and primary dysmenorrhoea (menstrual cramps), and may assist with the pain of osteoarthritis. This medication is commonly used in clinical settings marked by heightened patient distress from sudden, short-term pain episodes, such as those following mild sprains, strains, or minor procedures like dental extractions.

It is applicable in conditions marked by periods of heightened symptoms, and its primary therapeutic benefit contributes to easing the overall symptom load during difficult episodes. The medication is applied in addressing the often-pronounced lower abdominal cramping and discomfort, supporting comfort during difficult episodes. Sulidor also supports the symptomatic management of elevated body temperature (fever) and the general systemic aches that accompany a febrile state.


Quick Fact: Relief for Acute Discomfort Sulidor is commonly used to help manage symptom clusters that involve pain and localized swelling, and is applied across domains where additional symptomatic support is needed.


Regulatory References

  1. European Medicines Agency

Eligibility and Restrictions for Use

Who Can and Cannot Use Sulidor? (Nimesulide Eligibility)

The use of Sulidor is strictly defined by regulatory agencies and is generally limited to short-term treatment in specific populations. The medicine is officially contraindicated (absolutely prohibited) for numerous patient groups:

Age-Related Eligibility Rules:

  • Contraindicated for children under 12 years of age.
  • Permitted for adolescents (12+) and adults, though caution and monitoring are advised for the elderly.

Contraindications (Absolute Non-Eligibility):

  • Patients with any degree of hepatic impairment (liver disease) or a history of prior hepatotoxic reactions to Nimesulide.
  • Individuals with severe renal impairment (creatinine clearance < 30 mL/min) or severe heart failure.
  • Patients with an active gastric or duodenal ulcer, a history of recurrent gastrointestinal bleeding, or severe bleeding disorders.
  • Women who are in the third trimester of pregnancy or are breastfeeding.
  • Individuals with known hypersensitivity to Nimesulide, aspirin, or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

Restricted or Conditional Use:

  • Patients with mild to moderate renal impairment or a history of certain gastrointestinal disorders (e.g., Crohn's disease) require special caution and clinical monitoring. The medicine is not recommended for women who are actively attempting to conceive.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sulidor (Nimesulide) has officially documented interaction patterns that establish constraints on co-administration, based primarily on government regulatory information.


Formally Documented Interaction Restrictions

Certain combinations are contraindicated according to official labeling. Co-administration is prohibited with other potentially hepatotoxic substances (e.g., other painkillers) due to the heightened risk of adverse hepatic reactions. Use is also contraindicated in the context of alcoholism, which prohibits co-exposure with alcohol.

Clinically Significant Exposure and Pharmacodynamic Interactions

The co-administration of Sulidor with several medicinal products may result in specific regulatory constraints or documented outcomes:

  • Anticoagulants (e.g., Warfarin): Increases the documented risk or severity of bleeding and hemorrhage.
  • Lithium and Methotrexate: Concomitant use may result in officially documented increased plasma concentrations of these medicines due to reduced clearance.
  • Diuretics and ACE Inhibitors/ARBs: Interaction may reduce their pharmacodynamic effect and carries a risk of deterioration of renal function.
  • Cyclosporin: May increase the documented risk of nephrotoxicity.

Population-Based Interaction Constraints

Official labeling contraindicates the use of Sulidor in patients with hepatic impairment and severe renal impairment (creatinine clearance <30 ,mathrmml / mathrmmin) due to the significant risk of drug or active metabolite accumulation.

Mechanism of Action

Mechanistic Action on the Wnt/β-Catenin Pathway

Sulidor is a selective modulator targeting the Wnt/β-catenin signaling cascade. Its primary interaction is as an allosteric modulator of the low-density lipoprotein receptor-related protein 5 (LRP5), a co-receptor for Wnt ligands. This molecular interaction leads to the stabilization of beta-catenin within the cytoplasm of osteoblasts.

By stabilizing beta-catenin, Sulidor facilitates its nuclear translocation and subsequent binding to T-cell factor/lymphoid enhancer factor ( TCF/ LEF) transcriptional complexes. This binding modulates the expression of several Wnt-target genes. Specifically, the activity of Sulidor leads to a reduction in the transcription of the SOST gene, which encodes sclerostin, a known inhibitor of bone formation. The resulting decrease in sclerostin levels promotes the proliferation and differentiation of osteoblasts. This molecular cascade ultimately produces an anabolic effect on bone tissue.

Dosage and Administration Information

How to Use Sulidor: Official Administration Guidelines

Sulidor (Nimesulide) is administered according to strict dosage and time limits defined in official guidelines and the Summary of Product Characteristics (SmPC). The instructions cover two primary administration routes: oral for systemic effects and topical for localized use.

Standard Dosage and Frequency

Administration Route Standard Adult Regimen Key Administration Rules
Oral (Systemic) 100 mg twice daily (bid). The total daily dose must not exceed 200 mg. Must be taken after meals (post cibum) to ensure proper use.
Topical (Localized) Apply 3% gel 2 to 3 times per day (a 6-7 cm line, approx. 3 g). Massage until completely absorbed; do not use with occlusive dressings.

Use Duration and Population Guidelines

Oral treatment with Sulidor must be limited to the shortest possible duration and should not exceed 15 days. This strict time limit is established in official documents to govern overall use.

Population Rules:

  • Older Adults and Adolescents (12-18 years): Generally, no dosage adjustment is required based on the adult regimen.
  • Renal Function: No dosage adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance 30-80 mL/min). Oral systemic forms are contraindicated in children under 12 years of age, as specified in the official labeling.

Official Instructions Summary:

These guidelines define the correct procedural structure for using the medicine. The consistent pattern requires the oral 100 mg dose to be taken following food, repeated twice daily, and restricted to a maximum treatment course of fifteen days. This ensures the medicine is used precisely according to defined parameters.

Recent Clinical Evidence

Research evidence / Overview of studies for Sulidor

Evidence for Acute Pain Management and Fever

This section summarizes the research base for studies examining symptoms associated with acute pain and fever, focusing on the types of Randomized Controlled Trials (RCTs) and systematic reviews conducted for these purposes.

The evidence for the short-term use in conditions involving periods of heightened symptoms primarily consists of many RCTs and subsequent systematic reviews. Research examined outcomes related to physical discomfort, primarily focusing on patient-reported outcomes describing perceived discomfort. Studies monitored how patient-reported outcomes describing perceived discomfort evolved during the short observation periods. Research explored the measured change in elevated body temperature. Findings describe patterns observed in studies examining changes in elevated body temperature. However, comparative evidence is lacking in large-scale modern RCTs focused solely on this effect against certain major alternative medications.


Evidence for Primary Dysmenorrhoea

This part details the specific clinical trials and meta-analyses that have examined the symptomatic use of the medicine for primary menstrual cramps, describing the studied patient groups and the outcomes evaluated.

Research focused on conditions characterized by fluctuating or episodic manifestations involving outcomes describing episodic or acute changes in lower abdominal pain. Studies focused on episodes where symptoms become more noticeable and evaluated changes in patient-reported pain scores. The research describes patterns related to how patient-reported outcomes evolved during periods of heightened symptom activity.

Study results reflect the specific conditions under which they were conducted, not personal outcomes for individual patients for primary dysmenorrhoea. The follow-up durations were limited, typically restricted to observations over one or two painful cycles. Data for longer-term management or for women whose symptoms may vary in intensity over many cycles remains limited.


Historical Research for Osteoarthritis Symptoms

Historically, older clinical trials explored the drug's use in conditions marked by functional limitations, such as painful osteoarthritis of the knee or hip. These studies were used in research exploring how symptoms change over time and measured outcomes reflecting daily functioning or activity level. Evidence derived from settings with varying symptom burdens was used in research exploring patient-reported experiences. However, regulatory decisions in many regions have since restricted the use of the systemic (oral) forms of Sulidor to acute, short-term use only (maximum of 15 days). Therefore, the findings related to long-term use in chronic conditions like osteoarthritis are generally not relied upon by regulators when determining the current labeled use of the medicine.


Duration of Study and Long-term Follow-up

Evidence for Sulidor's systemic use is derived from studies that primarily observed responses over defined time intervals that are quite short. For its acute pain and dysmenorrhoea indications, the follow-up durations were limited to a maximum of 15 days, reflecting the regulatory restriction on the length of time the medicine can be taken continuously. The research describes short-term changes and the time frame of symptom management during an acute episode. However, long-term effects are not fully established because the drug is not intended for chronic use. There is limited information for long-term outcomes or the durability of observed changes beyond the 15-day limit.

Key Studies & References

  1. Nimesulide: systematic review of its safety and efficacy in the treatment of osteoarthritis and other painful conditions
  2. Nimesulide: benefits and risks. A systematic review of the literature and of data from the Italian Pharmacovigilance System

Frequently Asked Questions (FAQ)

Common questions about Sulidor (FAQ)


Q: How quickly should I expect to feel the pain-relieving effects of Sulidor?

Studies and official information indicate that the active ingredient, Nimesulide, has a relatively rapid onset of action. Clinical data indicates that pain-relieving effects are often reported to begin within 30 minutes to a few hours after administration, though individual response times can vary.


Q: What are the signs of a more serious side effect of Sulidor that I should look out for?

Regulatory documents state that serious side effects are possible, particularly concerning the liver. Signs that may indicate a serious side effect include unexplained fatigue, dark urine, abdominal pain, loss of appetite (anorexia), vomiting, or yellowing of the skin or eyes. If these symptoms are noticed, a medical professional should be consulted promptly.


Q: Is it normal to feel dizzy or have a slight headache when starting Sulidor?

Yes, regulatory documentation lists headache and dizziness (vertigo) as known adverse effects of Sulidor. These effects are generally classified as uncommon or very rare, but they may occur when starting the medication.


Q: Can I safely take Sulidor with a daily low-dose aspirin for heart protection?

Official product information indicates that taking Sulidor with aspirin (acetylsalicylic acid) may increase the risk of bleeding or hemorrhage. Regulatory warnings state that if this combination is considered, it requires careful medical supervision and assessment of the individual bleeding risk.


Q: Is Sulidor safe for older adults, and are there special considerations for them?

Official documentation notes that older adults may have an increased frequency of serious adverse reactions, especially those affecting the stomach and intestines. This population requires careful risk assessment when considering use. Regulatory guidelines emphasize using the lowest effective dose for the shortest possible duration for all patients, which is a key consideration for older adults.


Q: What is the duration of action for Sulidor, meaning how long does one dose last?

Regulatory guidance and pharmacokinetic data indicate that the half-life of the drug is roughly 2 to 5 hours. Pharmacokinetic data shows that the half-life of the drug is roughly 2 to 5 hours. The twice-per-day administration schedule is aligned with the need to maintain therapeutic levels.


Q: If I miss a dose of Sulidor, what is the best way to proceed?

According to general patient guidance, if a dose is missed, it is usually advised to take it as soon as remembered, unless it is almost time for the next scheduled dose. It is important not to take a double dose to compensate for a forgotten dose. Specific instructions are provided in the medication’s Patient Leaflet.


Q: Do you have to take Sulidor with food, and what happens if you take it on an empty stomach?

Official labeling specifies that Sulidor tablets should be taken after meals. This instruction is given to ensure the proper use of the medicine and to help reduce the possibility of stomach upset or other gastrointestinal side effects.


Q: Is Sulidor a type of sulfa drug, and can people with a sulfa allergy take it?

The active ingredient, Nimesulide, is related to the sulfonamide class of compounds. Official information states that the medicine is contraindicated (prohibited) if there is a known hypersensitivity or allergy to Nimesulide or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs).


Q: What specific pain conditions is Sulidor most commonly prescribed for?

According to regulatory indications, Sulidor is approved only for the short-term treatment of two specific conditions: acute pain and the symptomatic treatment of primary dysmenorrhoea (menstrual cramps).


Q: What is the mechanism of action that explains how Sulidor reduces inflammation?

Official regulatory information states that Sulidor functions primarily as a selective inhibitor of the COX-2 enzyme. This enzyme is chiefly responsible for generating the chemical mediators (prostaglandins) that lead to the signs of pain, fever, and inflammation.


Q: Can Sulidor be used for general body aches and pains, or only for specific conditions?

Regulatory approval specifies that Sulidor is limited to short-term treatment for acute pain and primary dysmenorrhoea. Its use is subject to a strict maximum duration of 15 days, which restricts its use for chronic or general aches.


Q: Does Sulidor increase the risk of heart-related issues, and if so, what are the symptoms?

Like other medicines in the NSAID class, regulatory documents indicate a possible small risk of serious cardiovascular events, such as a heart attack or stroke. Use is prohibited (contraindicated) for patients with severe heart failure. Symptoms that may be associated with cardiovascular events include chest pain, shortness of breath, or weakness.


Q: Does Sulidor have different interactions if taken as a tablet versus a topical gel?

The topical gel is for localized use and has very low systemic absorption, meaning that systemic adverse reactions and drug-drug interactions are generally considered unlikely. However, the risk is still possible if the gel is applied to large areas of skin or used for a long period of time.


Q: Is Sulidor a prescription-only medication in most countries?

Where its use is authorized, the systemic (oral) formulation of Sulidor is typically classified as a prescription-only medicine. This restriction is in place due to the need for medical supervision and monitoring for potential side effects.


Q: Can taking Sulidor for a long time lead to different side effects than short-term use?

Yes. Official regulatory documents strictly limit treatment duration to a maximum of 15 days. This restriction is in place to help mitigate the risk of serious adverse reactions, especially liver injury (hepatotoxicity), which is a key safety concern with prolonged use.


Q: What are the known drug-drug interactions involving Sulidor and blood thinners?

Co-administration with blood thinners, such as anticoagulants (like Warfarin), is known to increase the documented risk or severity of bleeding and hemorrhage. If this combination is considered, close monitoring of the patient's blood coagulation status is typically required.


Q: Could Sulidor potentially cause changes in mood or sleep patterns?

Regulatory documents list somnolence (drowsiness) as a very rare central nervous system adverse effect. If a patient experiences dizziness or somnolence, the product labeling advises caution regarding activities such as driving or operating heavy machinery.


Q: What is the active ingredient in the topical gel form of Sulidor?

The active substance in all forms of Sulidor, including the topical gel, is Nimesulide.


Q: How does the topical gel form of Sulidor work differently than the oral tablets?

The oral tablets are designed to be absorbed into the bloodstream for a systemic (whole-body) pain-relieving effect. In contrast, the topical gel is applied directly to the skin for a localized anti-inflammatory and analgesic effect in a specific area.


Q: What are the signs of a rare, severe skin reaction related to Sulidor?

Severe skin reactions, such as Stevens-Johnson syndrome, are very rare but require immediate attention. The signs of a severe skin reaction may include the development of a widespread rash, fever, blistering, or painful sores (lesions) in the mouth, throat, eyes, or genital area. Immediate medical attention is required if these are noticed.

How should Sulidor be stored and disposed of?

The storage and disposal of Sulidor (Nimesulide) are strictly governed by regulatory requirements to ensure product stability and safety.

Required Storage Conditions

The medicine must be stored at a controlled room temperature, not exceeding 25^circC (seventy-seven degrees Fahrenheit). It is mandatory to keep the product in its original package and store it in a dry place, protected from light and moisture. The product must not be frozen.

Stability and Child Safety

The medicine must not be used after the expiration date. For forms prepared from granules, the resulting suspension has a limited, specific in-use shelf-life. To ensure child safety, the product must be kept out of the sight and reach of children at all times.

Official Disposal Rules

Unused or expired Sulidor must be disposed of according to local regulatory requirements. Disposal in wastewater or household waste is prohibited to protect the environment. The product should be returned to a pharmacist or an official collection point for proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulidor found in:

A-Z Index: